Sophie Maïga

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose, Joel D. Leverson, Franklin Peale et al. · Molecular Cancer Therapeutics · 2016 · 309 citations

Medicine, Pharmacology, Chemotherapy +11

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Benoît Tessoulin, Géraldine Descamps, Philippe Moreau et al. · Blood · 2014 · 165 citations · Full text

Medicine, Cancer Biology, Oncology +14

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

Jérôme Moreaux, Bernard Klein, Régis Bataille et al. · Haematologica · 2010 · 162 citations · Full text

Medicine, Cell Biology, Hematology +16

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Linda Bodet, Patricia Gomez‐Bougie, Cyrille Touzeau et al. · Blood · 2011 · 124 citations · Full text

Medicine, Hematology, Oncology +11

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Patrick Casara, James Davidson, Audrey Clapéron et al. · Oncotarget · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17